METHODS: In this single-center retrospective cohort study, we analyzed data from 167 female patients diagnosed with HER2-positive breast cancer who were treated with trastuzumab. We meticulously assessed the level of adherence to cardiac monitoring guidelines and determined the incidence of trastuzumab-induced cardiotoxicity (TIC). Factors affecting adherence were subsequently investigated using appropriate statistical methods.
RESULTS: Adherence to monitoring guidelines was only 31.7%. TIC incidence was 7.8%. Patients with concurrent use of cardiotoxic medications demonstrated higher adherence. A significant association was found between the number of trastuzumab doses and adherence.
CONCLUSIONS: Adherence to monitoring guidelines was suboptimal. Those at a higher risk of cardiac issues showed greater adherence. Improved risk assessment methods are needed to individualize monitoring and intervention. Future research should focus on patient-centered, evidence-based monitoring to optimize the balance between cancer therapy and cardiac safety in the field of cardio-oncology.
方法:在这项单中心回顾性队列研究中,我们分析了167例HER2阳性乳腺癌女性患者接受曲妥珠单抗治疗的数据.我们仔细评估了心脏监测指南的依从性,并确定了曲妥珠单抗诱导的心脏毒性(TIC)的发生率。随后使用适当的统计方法调查影响依从性的因素。
结果:对监测指南的依从性仅为31.7%。TIC发生率为7.8%。同时使用心脏毒性药物的患者表现出更高的依从性。发现曲妥珠单抗剂量数与依从性之间存在显著关联。
结论:对监测指南的依从性并不理想。那些心脏问题风险较高的患者表现出更高的依从性。需要改进风险评估方法,以个性化监测和干预。未来的研究应该集中在以患者为中心,基于证据的监测,以优化心脏肿瘤领域癌症治疗和心脏安全性之间的平衡。